Home

Dexcel Pharma Technologies Ltd.

CIK 1720007 · last filed 2022-11-14

Dexcel Pharma Technologies Ltd. is a corporate insider who has filed 12 SEC Form 4 insider transactions across 5 companies since 2017. The most recent filing shows the insider bought $60.0M of ROIVW on Nov 14, 2022. Across all open-market trades the lifetime net is +$57.6M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $10.0M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$9.98M

Companies

5

Total Filings

12

Lifetime Open-Market Net

$57.64M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Roivant Sciences Ltd. (ROIVW) Delisted 10%+ Owner 102,849,443 $2.75 $282.84M $60.00M 1 2022-11-14
PLX 10%+ Owner 4,494,820 $2.22 $9.98M -$4.18M 1 2021-06-03
Intec Pharma Ltd. (NTEC) Delisted 10%+ Owner 4,344,897 $9.63 $41.84M -$563.3K 1 2020-02-04
Urovant Sciences Ltd. (UROV) Delisted 10%+ Owner 22,841,809 $16.24 $370.95M $2.38M 6 2019-06-14
ABUS 10%+ Owner — $4.55 — $0 2 2018-01-16

Recent Filings

12 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-11-14 Roivant Sciences Ltd. (ROIVW) Delisted Buy (P) +12,000,000 $60.00M EDGAR
2021-06-03 PLX Sell (S) −1,837,434 -$4.18M EDGAR
2020-02-04 Intec Pharma Ltd. (NTEC) Delisted Sell (S) −1,831,902 -$563.3K EDGAR
2019-06-14 Urovant Sciences Ltd. (UROV) Delisted Buy (P) +66,033 $531.9K EDGAR
2019-06-11 Urovant Sciences Ltd. (UROV) Delisted Buy (P) +64,014 $531.7K EDGAR
2019-06-06 Urovant Sciences Ltd. (UROV) Delisted Buy (P) +63,366 $497.9K EDGAR
2019-05-29 Urovant Sciences Ltd. (UROV) Delisted Buy (P) +43,455 $331.4K EDGAR
2019-05-28 Urovant Sciences Ltd. (UROV) Delisted Buy (P) +29,505 $233.4K EDGAR
2019-05-23 Urovant Sciences Ltd. (UROV) Delisted Buy (P) +29,985 $255.3K EDGAR
2018-06-07 — Buy (P) +42,857,142 $75.00M
Showing 1–10 of 12
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.